论文部分内容阅读
目的:观察抗肿瘤药物华蟾素联合研究光动力疗法直肠给药对载承黏膜的影响。方法:用华蟾素联合新型光敏剂甲酯化叶绿素(MECD)治疗移植性H22肝癌和单一使用华蟾素及PDT作比较,观察抑瘤率及直肠黏膜的病理改变。结果:PDT联合华蟾素组、华蟾素组、PDT组的抑瘤率分别为,H22:51.69%、33.49%、26.50%,病理提示MECD光敏剂直肠给药对载承黏膜有一定损伤,但未见明显血便。结论:华蟾素联合MECD光敏剂直肠给药方式疗效可靠,无明显不良反应,是有可行意义值得提倡推广。
Objective: To observe the effect of cinobufacini combined with anti-tumor drug on the bearing mucosa of rectum with photodynamic therapy. Methods: The inhibitory rate of tumor and the pathological changes of rectal mucosa were observed by using cinobufacini combined with a new photosensitizer methyl ester chlorophyll (MECD) for the treatment of transplanted H22 hepatocellular carcinoma and single use of cinobufacini and PDT. Results: The tumor inhibition rates of PDT combined with cinobufacini, cinobufotalin and PDT were H22: 51.69%, 33.49% and 26.50%, respectively. The pathology suggested that rectal administration of MECD photosensitizer had some damage to the bearing mucosa, But no obvious bloody stools. Conclusion: Cinobufacini combined with MECD photosensitizer rectal administration of reliable efficacy, no obvious adverse reactions, is worthy of promotion is worth promoting.